The cardiovascular protective mechanisms of GLP-1 receptor agonists are thought to include: Improved glycaemic control , reducing endothelial dysfunction associated with hyperglycaemia Weight reduction , decreasing metabolic stress and inflammation Blood pressure lowering , potentially through effects on fluid balance and vascular function Favourable lipid profile changes , including modest reductions in LDL cholesterol and triglycerides Anti-inflammatory effects , reducing systemic markers of inflammation such as C-reactive protein Regulatory bodies including the MHRA and EMA have not identified thrombotic events as a specific safety concern with GLP-1 receptor agonists
All the analyses were carried out at the IZW in Berlin
At a 5 mg/mL concentration, a 2 mg dose means drawing exactly 0.4 mL
It covers key points such as selecting an appropriate injection site, preparing the injection site, and injecting the medication correctly
Mnico A, Guzmn-Caldentey J, Pajares MA et al (2021) Molecular insight into the regulation of vimentin by cysteine modifications and zinc binding
